[Treatment of recurrent herpes labialis using a herpes simplex Type-I subunit vaccine. A prospective randomized double-blind multicenter study].
A herpes simplex type I subunit vaccine developed by Behring-Werke (Marburg/Lahn, FRG) was compared with placebo for therapeutic effectiveness in the treatment of recurrent orolabial herpes simplex in a multicentre study involving the major hospitals in Frankfurt/Main (n = 34), Hamburg (n = 18), Giessen (n = 17) und Kassel (n = 14). The effectiveness of the vaccine was judged on the reduction in the frequency of recurrences. Within the period of the 8-month study there was no statistically significant difference in the frequency of recurrences with vaccine or placebo. Both placebo and verum led to a significant decrease in the number of recurrences of orolabial herpes simplex, but the effect of placebo was slightly more pronounced.
Altmeyer
P
P
Zentrum für Dermatologie und Venerologie, J.W. Goethe-Universität Frankfurt/Main.
Wehrenberg
O
O
Holzmann
H
H
Paul
E
E
Kimmig
W K
WK
Wassilew
S W
SW
Petres
J
J
Korger
G
G
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006560:Herpes Labialis / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D018139:Simplexvirus / Q000276:immunology*; D013283:Stomatitis, Herpetic / Q000517:prevention & control*; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000302:isolation & purification / Q000627:therapeutic use*
D014759:Viral Envelope Proteins; D014765:Viral Vaccines
Behandlung des rezidivierenden Herpes labialis mit einer Herpes-simplex-Typ-I-Subunit-Vakzine. Eine prospektive randomisierte doppelblindkontrollierte Multicenter-Studie.